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ABSTRACT
We retrospectively analyzed results of unrelated cord blood transplantation (UCBT) in 93 Fanconi anemia (FA)
patients. Median age at transplantation was 8.6 years (1-45). The units transplanted were HLA-A, -B, or
-DRB1 identical in 12 cases, 1 HLA mismatch in 35 cases, and 2 or 3 HLA differences in 45 cases. The median
number of nucleated cells (NC) and CD34 cells infused of recipient weight was 4.9 107/kg and 1.9 105/kg,
respectively. Participating centers selected the preparative regimen of their choice, in 57 patients (61%), it
included Fludarabine. Graft-versus-host disease (GVHD) prophylaxis consisted mostly of cyclosporine with
prednisone. Cumulative incidence (CI) of neutrophil recovery was 60  5% at day 60. In multivariate
analysis, Fludarabine containing regimen and NC infused >4.9  107/kg were associated with higher proba-
bility of recovery. CI of grade II-IV acute and of chronic GVHD (aGVHD, cGVHD) was 32%  5% and 16%
 4%, respectively. Overall survival (OS) was 40%  5%. In multivariate analysis, factors associated with
favorable outcome were use of Fludarabine in the conditioning regimen, number of NC infused>4.9 107/kg,
and negative cytomegalovirus (CMV) serology in the recipient. In conclusion, factors easily modifiable such as
donor selection and a Fludarabine-containing regimen can considerably improve survival in FA patients given
a UCBT. These data are the basis for designing prospective protocols.
© 2007 American Society for Blood and Marrow Transplantation
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FNTRODUCTION
Fanconi anemia (FA) is clinically characterized by
ongenital abnormalities, progressive bone marrow fail-
re, and predisposition to malignancy, especially acute
yelogenous leukemia (AML) and squamous cell carci-
oma (SCC) [1]. Cells derived from FA patients are
ypersensitive to DNA crosslinking agents, such as mi- Fomycin C (MMC) and diexpoxybutane (DEB), suggest-
ng that the FA pathway may be involved in the sensing
nd/or repair of interstrand crosslinks. Cell fusion exper-
ments have identiﬁed at least 13 different complemen-
ation groups, and 12 of their corresponding disease
enes have been cloned: FANCA, FANCB, FANCC,
ANCD1/BRCA2, FANCD2, FANCE, FANCF,
ANCG, FANCJ/BRIP1, FANCL , FANCM1-1,
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E. Gluckman et al.1074nd FANCN [1-4]. Mutations in 1 of the FA comple-
entation groups prohibit FA complex formation, re-
ulting in disruption of DNA repair. Hematopoietic
tem cell transplantation (HSCT) is the only curative
ption for the hematologic manifestations of the syn-
rome, although it does not prevent the late occur-
ence of secondary solid tumors, mostly head and
eck SCC [5-7]. It is well known that conventional
onditioning regimens, including immunosuppres-
ive drugs (cyclophosphamide) induce signiﬁcant
oxicity [8-10]. Improved conditioning regimens us-
ng low-dose cyclophosphamide resulted in a 5-year
urvival of approximately 80% for HLA identical re-
ated transplant [11-13]. However, even in the HLA
dentical transplant setting, FA patients remained at
ncreased risk of severe graft-versus-host disease
GVHD) when compared to patients with severe id-
opathic aplastic anemia, because the defective DNA
epair machinery renders tissues more prone to be-
ome a target of the alloreactive aggression leading to
VHD [14]. Results of HSCT were inferior when the
onor was an unrelated volunteer or an HLA mis-
atched relative, because of increased risk of rejec-
ion, when the graft was T cell depleted, or increased
ncidence of GVHD, if the transplant remained T
eplete [15,16]. Recently, Fludarabine, a nucleotide
nalog, has been introduced to a variety of myeloab-
ative and nonmyeloablative preparative regimens,
ainly because of its immunosuppressive properties.
se of Fludarabine in the conditioning regimen of
nrelated bone marrow transplant recipients with FA
as been reported in a small series, and in a large
ohort of patients and it was found to be associated
ith improved outcome [17-19]. Cord blood is an
ttractive source of hematopoietic stem cells for pa-
ients who lack an HLA-matched unrelated bone mar-
ow donor. The low incidence of GVHD associated
ith unrelated cord blood transplantation (UCBT)
ay also be advantageous for FA patients, given the
reviously mentioned risk [20]. FA is a rare and het-
rogeneous disease, and only multicenter retrospec-
ive studies can gather enough patients for analyzing
esults and prognostic factors. We studied the clinical
esults and risk factors for outcomes of UCBT in FA
atients as reported to the Eurocord Registry.
ATIENTS, MATERIALS, AND METHODS
ata Collection and Patient Selection
This retrospective analysis is based on data re-
orted to the Eurocord Registry from 26 European
nd non-European centers through a standardized
uestionnaire concerning patient, UCB units, disease
nd graft characteristics, as well as transplant out-
omes. The collected information was reviewed by 2
hysicians and checked for computerized errors to
nsure data quality. bAll patients or their legal guardians gave informed
onsent for UCBT according to the Declaration of
elsinki. The present study was approved by the Eu-
ocord institutional review board.
ndpoint Definition
Neutrophil recovery was deﬁned as the ﬁrst of 3
onsecutive days when neutrophils were 0.5 
09/L and platelet engraftment as the ﬁrst of 7 con-
ecutive days with an unsupported platelet count20
09/L. Absence of hematopoietic recovery at day 60,
econd transplantation, or autologous hematopoietic
econstitution was considered as failure to engraft.
Acute GVHD (aGVHD) was scored from day 1
ccording to the standard criteria and counted only for
rades 2. Patients surviving for100 days after trans-
lantation with sustained donor hematopoiesis were
onsidered at risk for development of chronic GVHD
cGVHD). Transplant-related mortality (TRM) was de-
ned as all causes of death occurring at any time after
CBT and not related to the underlying disease.
verall survival (OS) was measured by the time inter-
al between the date of transplantation and the date of
eath for any cause or the date of the last follow-up for
urvivors.
tatistical Analysis
Analysis used March 1, 2006, as the reference date,
hat is, the day at which all centers locked data on
atient outcomes. Two patients were lost to follow-
p. Patient-, donor-, disease-, and transplant-related
ariables were analyzed for their prognostic value for
eutrophil and platelet recovery, grade II-IV aGVHD
nd survival. More precisely: disease (presence of mal-
ormations, number of red blood cell [RBC], and
latelet transfusions) patient and donor characteristics
such as age, weight, cytomegalovirus [CMV] serol-
gy, ABO compatibility, number of HLA disparities),
nd transplant-related factors (number of nucleated
ells collected and infused/kg recipient body weight,
ype of conditioning regimen, use of antithymocyte
lobulin [ATG]/antilymphocyte globulin [ALG] or
onoclonal antibody [mAb]).
Univariate and multivariate proportional hazard
egression models were used to identify independent
isk factors for death by means of log-rank tests and
ox proportional hazard models. For estimation of
umulative incidence for neutrophil and platelet re-
overy, grade II-IV aGVHD, cGVHD, and TRM, a
imilar methodology was used in a competing-risk
etting, death being treated as a competing event.
nivariate and multivariate analysis of neutrophil and
latelet recovery were then performed using Gray’s
est and the proportional subdistribution hazard re-
ression model of Fine and Gray [21,22]. A stepwise
ackward procedure was used to construct a set of
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Unrelated CBT in Fanconi Anemia 1075ndependent predictors of each endpoint. All predic-
ors achieving a P-value .10 were considered, and
equentially removed if the P-value in the multiple
odel was .05. All tests were 2 sided. The type I
rror rate was ﬁxed at 0.05 for determination of fac-
ors associated with time to event outcomes.
Because the use of Fludarabine was associated with
mproved engraftment and survival, we have com-
ared both group of patients (using or not using Flu-
arabine) according to the above-cited characteristics
nd toxicities after UCBT (such as hemorrhagic cys-
itis, veno-occlusive disease, interstitial pneumonitis,
nd acute respiratory distress syndrome). The com-
arison was performed using the exact Fisher test for
ategoric and the nonparametric Kruskal-Wallis test
or continuous variables.
Statistical analyses were performed with SPSS
Inc., Chicago) and Splus (Math Soft, Inc., Seattle,
A) software packages.
ESULTS
The study included 93 patients, with a minimum
ollow-up of 3 months, undergoing a UCBT for FA
rom 1994 to 2005. The median follow-up is 22
onths (3-121).
atients’ and Donors’ Characteristics
efore Transplantation
Details on patient, donor, and graft characteristics
re shown in Tables 1 and 2. All patients had a diag-
osis of FA conﬁrmed by the presence of multiple
hromosome breaks, enhanced by incubation with
rosslinking agents. The following information was
vailable: sex, date of birth, date of diagnosis, date of
ntry in the study, description of the clinical pheno-
ype, and blood cell counts. The complementation
roup was available for only 11 patients: it was A for 7
atients, C for 2 patients, G for 2 patients. (and “not
” for 2 patients without other precision). Malforma-
ive syndrome was classiﬁed as limited (3 sites) or
xtensive (3 sites) according to criteria previously
escribed [15]. At the time of UCBT, median granu-
ocyte count was 580/L (range: 0-5500). Twenty
atients had marrow cytogenetic clonal abnormalities,
nd 13 patients were diagnosed with myelodysplastic
yndrome (MDS) (n 8) or acute leukemia (AL) (n
) (including 3 with prior MDS). Only 1 of 5 patients
as in hematologic remission at the time of transplant.
Nine different conditioning regimens were used in
he 26 participating centers. They are described in
able 2. Among the 57 patients who received Fludara-
ine, 13 patients received cyclophosphamide 40
g/kg and 5 Gy total body irradiation (TBI), whereas
1 patients received cyclophosphamide and busulfan
8 mg/kg total dose). ATG or ALG were added in 15 cases. In the non-Fludarabine group, all 35 patients
eceived low-dose cyclophosphamide; it was associ-
ted with TBI 5 Gy in 22 cases, with total lymphoid
rradiation (TLI) 4 Gy in 6 cases or busulfan in 1 case.
TG/ALG was added in 29 cases and anti-T mAb in
cases. There were no statistical signiﬁcant differ-
nces of pretransplant and transplant characteristics
etween patients who did or did not receive Fludara-
ine. GVHD prevention consisted of cyclosporine A
ith prednisone or cyclosporine alone (71 cases) (see
lso Table 2 for details). The median number of nu-
leated cells and CD34 cells infused was 4.9 
07/kg (range: 1.0-19.2) and 1.9  105/kg (range:
.2-27.3), respectively. In all donor-recipient pairs,
istocompatibility was determined by serology or low
esolution molecular typing for HLA-A and -B anti-
ens and by allelic typing for -DRB1. Twelve patients
ere transplanted from an HLA identical donor, in 35
onor-recipient pairs there was only 1 HLA difference
equally distributed between -A, -B, or -DRB1 loci), in
0 pairs, there were 2 HLA differences (-A and -B in
7 cases, -A and -DRB1 in 6 cases, -B and -DRB1 in
able 1. Characteristics of the 93 Fanconi Anemia Patients Receiving
n Unrelated Cord Blood Transplant
Characteristics
(n  Available Information)
Number of
Patients (%)
alformative syndrome (n  84)
Absent 9 (11%)
Limited 53 (63%)
Extensive 22 (26%)
arrow clonal cytogenetic abnormality (n  81) 20 (25%)
bnormalities of chromosome 5 4
bnormalities of chromosome 7 2
ther abnormalities 14
retransplant treatment (n  78)
Steroids 5 (6%)
Androgens 26 (33%)
Steroids  androgens 22 (28%)
HGF 16 (21%)
Immunosuppressors (CsA, ATG) 9 (12%)
umber of pretransplant RBC transfusions
(n  81)
None 13 (16%)
1-19 47 (58%)
>20 21 (26%)
umber of pretransplant platelets transfusions
(n  89)
None 6 (7%)
1-19 55 (62%)
>20 28 (31%)
tatus at transplantation (n  93)
Aplastic anemia 81 (87%)
MDS 8 (9%)
AL 4 (4%)
edian granulocyte count at transplantation/L
(n  77) 580 (0-5500)
sA indicates cyclosporine A; ATG, antithymocyte globulin; MDS,
myelodysplastic syndrome; AL, acute leukemia; RBC, red blood
cells; HGF, hematopoietic growth factors.3 cases, 2 -DRB1 in 3 cases, and 2 -B in 1 case). The
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E. Gluckman et al.1076emaining 5 patients were transplanted from a donor
ho was disparate for 3 HLA loci (see also Table 2).
eutrophil and Platelet Recovery
Median time to neutrophil recovery was 23 days
range: 11-43 days). The cumulative incidence (CI) of
eutrophil recovery at 60 days was 60%  5%. In
nivariate analysis, factors favorably associated with
eutrophil recovery were 0 to 1 HLA differences ver-
us 2 (P  .05), 20 red blood cell (RBC) transfu-
ions before transplantation (P  .03), 4.9  107
ucleated cells infused/kg (P  .01) (Figure 1), recip-
able 2. Patient, Donor, and Transplant Characteristics of the 93 FA
Characteristics (n  Available Information)
ge, years (n  93 )
ale sex (n  93)
eight, kg (n  91)
ime from diagnosis to transplant, months (n  91)
revious allogeneic transplant (n  93)
ositive CMV serology (n  86)
BO compatibility (n  81)
dentical/minor/major incompatibilities
LA compatibility (n  92) (HLA-A, -B, low-resolution and DRB
high-resolution typing)
6 – of 6
5 – of 6
4 – of 6
3 – of 6
umber of nucleated cells at freezing, 107/kg (n  93)
umber of infused cells
nucleated cells, 107/kg (n  93)
CD34, 105/kg (n  44)
onditioning (n  93)
CY based
Alone
CY  irradiation (TBI, TLI)* other
CY Bu
ludarabine based
FluCYTBI**
FluTBI***
FluCYBu
Other (VP16ThioTBI)
Anti-T cells (ATG/ALG or mAb)
VHD prophylaxis (n  93)
CsA alone
CsA  PrednisoneATG
CsAMTX
FK506 associated
MMF associated
Other
arly hematopoietic growth factors (n  52)
or continuous variables, number of available patients are reported
MV indicates cytomegalovirus; CsA, cyclosporine A; ALG, ant
antibody; MTX, methotrexate; MMF, mycophenolate mofetil; T
CY, cyclophosphamide; Flu, Fludarabine; VP16, etoposide; Th
blood transplantation.
All except 1 had TBI or TLI 5 Gy.
*Thirteen patients with TBI 5 Gy, 28 patients without TBI.
**All patients with 2 Gy TBI.
Early means between day 0 to day 7 after UCBT.ent’s weight26 kg (P .03), and use of Fludarabine pn the conditioning (P  .02) (Figure 2 and Table 3).
n multivariate analysis, only the use of Fludarabine (P
.05) and a cell dose 4.9  107/kg (P  .03)
emained signiﬁcant (Table 4).
Median time to platelet recovery was 44 days
range: 15-172 days). The CI of platelet engraftment
t 180 days was 51%  7%. Factors associated with
latelet engraftment were similar to those found to
nﬂuence neutrophil engraftment with 83% engraft-
ent in HLA identical transplants compared to 49%
n those with 1 HLA mismatch, 27% in those with 2
r more HLA mismatches (P  .0004). The CI of
Receiving an Unrelated Cord Blood Transplant
Number of Patients (%) or Median (min-max)
8.6 (1.4-45.4)
39 (42%)
26.0 (9.0-71.0)
34.3 (0.3-161.4)
0
52 (60%)
36 (39%)/17 (18%)/28 (30%)
12 (13%)
35 (37%)
40 (43%)
5 (5%)
5.9 (0.8-24.0)
4.9 (1.0-19.2)
1.9 (0.2-27.3)
35 (38%)
6
28
1
57 (61%)
41
5
11
1 (1%)
78 (84%)
17 (18%)
54 (58%)
12 (13%)
2 (2%)
7 (8%)
1 (1%)
31 (60%)
ocyte globulin; ATG, antithymocyte globulin; mAb, monoclonal
tal body irradiation; TLI, total lymphoid irradiation; Bu, busulfan;
iotepa; GVHD, graft-versus-host disease; UBCT, unrelated cordPatients
1
.
ilymph
BI, to
io, Thlatelet recovery was 28% and 55% in patients
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Unrelated CBT in Fanconi Anemia 1077eceiving less or more than 4.9  107 NC/kg, re-
pectively (P  .003).
Data on chimerism are available for 36 of 56
atients who engrafted at day 60; 32 were complete
onor and 4 were mixed chimeras.
GVHD and cGVHD
The CI of grade II-IV aGVHD was 32% 5%. It
as 53%  6% in patients who had donor engraft-
ent. It was graded as 0 in 57 cases (61%), I in 6 cases
7%), II in 11 cases (12%), and III-IV in 19 cases
20%). The CI of cGVHD was 16%  4%. In uni-
ariate analysis, the only factor associated with
GVHD II was the degree of HLA compatibility
P  .01). No GVHD was observed in the group of 12
atients who received an HLA matched graft, whereas
he CI of grade II-IV aGVHD was 40%  8% and
4%  7% for patients transplanted from a donor
ith 1 or 2-3 HLA mismatches, respectively.
urvival
The 3-year probability of survival was 40% 5%.
n univariate analysis, favorable factors were: age
ounger than 16 years at transplant (P  .05), HLA
ompatibility (P  .009; Figure 3), 20 RBC trans-
usions before transplantation (P  .008), recipient’s
egative cytomegalovirus (CMV) serology (P 
0003), use of Fludarabine in the conditioning regi-
en (P .01; Figure 4)4.9 107 nucleated cells/kg
nfused (P  .04; Figure 5 and Table 3). In multivar-
ate analysis, these latter 3 factors remained statisti-
ally signiﬁcant (see also Table 4 for details).
Use of ATG/ALG in the conditioning regimen
as not associated with improved survival. Among 37
atients currently alive, 32 fully engrafted by day60.
ive patients who did not engraft by day 60 are alive
2 engrafted after day 60 and 3 after a successful
igure 1. Neutrophil recovery of 93 Fanconi anemia patients given
UCBT according to the number of nucleated cells infused.econd transplant). roxicity and Causes of Death
Hemorrhagic cystitis was observed in 18 of 75
atients (24%), liver veno-occlusive disease was ob-
erved in 10 of 72 patients (13%), interstitial pneumo-
itis in 16 of 70 patients (22%), and acute respiratory
istress syndrome in 14 of 69 patients (20%). There
as no statistical difference in toxicities between pa-
ients who did or did not receive Fludarabine.
Fifty-six patients died. The main cause of death
as infection in 17 cases (31%) (bacterial in 6 cases,
iral in 5 cases, and fungal in 6 cases), graft failure in
2 cases (associated or not with infections) (21%),
GVHD in 7 cases (12.5%), hemorrhage in 2 (3.5%),
nd other toxicities (adult respiratory distress syn-
rome, veno-occlusive disease, or multiorgan failure)
n 17 cases (31%). One additional patient died at 46
onths after UCBT of oral carcinoma.
Among the 13 patients with MDS or AL, only 2
urvived, with an observation time of 12 and 107
onths, respectively. The others died of transplant-
elated causes: graft failure, infection, or GVHD.
ISCUSSION
This registry-based study includes FA patients
ransplanted worldwide with an unrelated, mostly
LA mismatched, umbilical cord blood unit. We
ound that 2 factors were positively associated with
ngraftment and survival: higher cell dose, and inclu-
ion of Fludarabine in the conditioning regimen. HLA
ompatibility was also an important factor for both
utcomes, although not signiﬁcant in the multivariate
nalysis. Although there may be difﬁculty in ﬁnding a
ully or nearly matched donor, the addition of Flu-
arabine is easily accomplished. These modiﬁable fac-
ors can help transplant physicians, by selecting UCB
nits containing higher cell dose, and using Fludara-
igure 2. Neutrophil recovery of 93 Fanconi anemia patients given
UCBT according to the use of Fludarabine in the conditioningegimen.
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E. Gluckman et al.1078ine-based conditioning regimen, that may favorably
lter the outcome of UCBT in FA patients.
Cell dose is an important factor for engraftment
nd survival after UCBT. Usually the recommended
ose is 3  107 NC/kg at infusion [23-25]. The
bservation made in this study that a median cell dose
t cryopreservation of 6  107 NC/kg and upon
hawing of 5  107 NC/kg (1.9  105 CD34
ells/kg) is in agreement with a recent Eurocord re-
ort showing that the cell dose should be higher in
able 3. Univariable Analyses of Neutrophil Recovery and Overall Sur
Neutrophil
n %
verall 93 60
ge
<16 years 84 61
>16 years 9 56
ge (median)
<8.6 y 46 61
>8.6 y 47 60
eight (median)
<26.0 kg 43 67
>26.0 kg 48 52
resence of malformations
Absent (n  9) or limited (n  53) 62 57
Extensive 22 73
umber of red blood cells transfusions
0-20 60 65
>20 21 35
umber of platelet transfusions
0-20 61 66
>20 28 46
MV serology
Negative 34 68
Positive 52 52
BO compatibility
Matched minor 53 57
Major mismatched 28 57
LA disparities
6/6 12 75
5/6 35 66
4/6 (n  40) and 3/6 (n  5) 45 51
C at freezing/kg
<5.9  107 46 50
>5.9  107 47 70
C Infused/kg
<4.9  107 46 50
>4.9  107 47 70
D34 infused/kg
<1.9  105 22 41
>1.9  105 22 68
tatus at transplant
Aplastic anemia 80 61
MDS or leukemia 13 51
se of irradiation
No 46 70
Yes 47 51
se of Fludarabine
No 36 42
Yes 57 72
CBT indicates unrelated cord blood transplant; CMV, cytomegaCBT for patients with nonmalignant diseases com- pared to patients transplanted with malignant disor-
ers. Possible hypothesis for this is the increased risk
f graft failure because of alloimmunization induced
y multiple transfusion exposure and also, because
hey did not receive any chemotherapy or immuno-
uppression before transplant [25]. Transplantation of
higher cell dose should be met easily because of the
oung age and small size of FA patients. Another
ossibility to increase cell dose is the use of double
ord blood transplantation, which in Fanconi anemia
ter UCBT for Fanconi Anemia
ery (CI) 3-Year Survival (K-M)
P Death %  SD P
56 40  5
48 42  5
.79 8 0 .05
25 45  7
.69 31 35  7 .07
22 49  8
.03 34 30  7 .01
37 38  6
.06 13 45  11 .99
33 46  7
.03 18 10  7 .008
31 46  7
.11 19 29  9 .28
12 64  8
.19 39 26  6 .0003
31 41  7
.75 18 36  9 .83
3 74  13
19 48  9
.05 33 25  7 .009
32 28  7
.02 24 51  7 .03
32 31  7
.01 24 49  7 .04
15 28  10
.06 10 54  11 .18
45 43  6
.31 11 23  12 .19
24 47  7
.13 32 32  7 .21
28 25  7
.02 28 50  7 .01
NC, nucleated cells; MDS, myelodysplastic syndrome.vival af
s Recov
 SD
 5
 5
 18
 7
 7
 7
 7
 6
 10
 7
 11
 6
 9
 8
 7
 7
 10
 14
 8
 8
 8
 7
 8
 7
 11
 10
 6
 15
 7
 7
 8
 6atients deserves further investigation.
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Unrelated CBT in Fanconi Anemia 1079HLA disparity is another factor important for en-
raftment, GVHD, and survival. Although HLA com-
atibility in patients given matched unrelated bone
arrow transplantation usually requires 9 or 10 allelic
atches for HLA-A, -B, -C, -DRB1, and -DQB1 loci
or selection of an optimal donor, HLA compatibility
n UCBT is usually assessed by serology or low-reso-
ution typing for HLA-A and -B and high-resolution
llelic typing for -DRB1. In a previous study, we have
ound that in UCBT, HLA was an important factor
or engraftment and occurrence of grade III-IV
VHD but it did not affect OS in patients with
alignant disorders [23,25]. In the present series of
atients, the best HLA match was found to be a
avorable factor for engraftment and survival (see Fig-
re 3) in univariate analysis; however, not in multivar-
ate analysis. This latter result has to be analyzed
able 4. Multivariate Analyses of Risk Factors for Overall Survival
nd Neutrophil Recovery after UCBT for Fanconi Anemia
Outcomes and Risk Factors
Hazard Ratio
(95% Confidence Interval)
P
Value
eutrophil recovery*
Use of Fludarabine 1.86 (0.99-3.47) .05
Number of nucleated cells
infused >4.9  107/kg 1.78 (1.07-2.97) .03
urvival**
Recipient’s CMV negative
serology 2.82 (1.45-5.49) <.001
Number of nucleated cells
infused >4.9  107/kg 1.75 (0.99-3.16) .05
Use of Fludarabine 1.79 (1.02-3.13) .04
CBT indicates unrelated cord blood transplantation; CMV,
cytomegalovirus.
Fine and Gray model.
*Cox model.
igure 3. Survival of 93 Fanconi anemia patients given a UCBT
ccording to HLA compatibilities. aautiously because there were few HLA-matched
ransplants and because we did not ﬁnd any difference
etween 0 or 1 HLA mismatches (see also Table 3).
hus, based on a previous analysis and this study, we
ecommend that cord blood unit selection in patients
ith nonmalignant disorders should contain a higher
ell dose. The effect of HLA will be counterbalanced
y cell dose but selection of units with more than 2
LA disparities should be avoided.
Conditioning with Fludarabine was also identiﬁed
s a favorable factor for engraftment and survival.
nfortunately, the multiplicity of conditioning regi-
ens used in this study restricts our ability to identify
igure 4. Survival of 93 Fanconi anemia patients given a UCBT
ccording to the use of Fludarabine in the conditioning regimen.
igure 5. Survival of 93 Fanconi anemia patients given a UCBT
ccording to the number of nucleated cells infused.
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E. Gluckman et al.1080preferable preparative regimen. Randomized studies
re extremely difﬁcult to conduct considering the rar-
ty of the disease and the difﬁculty of recruiting pa-
ients in a reasonable time period [26]. Many non-
ludarabine reduced intensity conditioning (RIC)
egimens have been reported, with a survival ranging
etween 20% to 40% [15,28-34]. Fludarabine mono-
hosphate, a purine analog-inhibiting adenosine
eaminase, has been demonstrated to display a potent
mmune-suppressive effect and has been used success-
ully before allogeneic HSCT in patients who are not
ligible for conventional myeloablative conditioning,
ecause regimens including this drug are well toler-
ted and have limited extra-medullary toxicity [27], an
dvantage in patients with DNA breakage susceptibil-
ty. This immunosuppressive effect is probably impor-
ant for engraftment in patients heavily transfused
efore transplantation. We found that Fludarabine-
ontaining regimens were associated with better out-
ome than other regimens (see also Table 3 and 4 and
igure 4 ). The favorable role of Fludarabine in the
onditioning of FA has been described in single cen-
ers reports [28-44]. We could speculate that patients
iven Fludarabine should experienced lower incidence
f aGVHD, because of its immunosuppressive prop-
rties; however, in our study there was no statistical
ifference in the cumulative incidence of aGVHD
ccording to the use of Fludarabine (data not shown).
ore recently, J. Wagner and colleagues [17] ana-
yzed 98 cases of patients with FA who were trans-
lanted with an unrelated matched or 1 antigen mis-
atched bone marrow donor. They showed that the use
f Fludarabine improved neutrophil recovery, decreased
00 days TRM, and improved 3-year adjusted OS
ate, which was 52% and 13% in patients who did or
id not receive Fludarabine, respectively (P  .001).
VHD was reduced in patients who received a T
ell-depleted bone marrow transplant (21% versus
0%). We found a grade II-IV aGVHD CI of 32% 
% in our cohort of patients, thus suggesting that the
eduction of GVHD after UCBT might be equivalent
o that observed in patients given a T cell depletion
f unrelated bone marrow graft. Although we did
ot formally compare UCBT to unrelated bone
arrow transplantation (BMT) outcomes, both
agner et al.’s study and our analysis show that the
se of Fludarabine is able to improve the prognosis
f unrelated donor allograft in patients with FA
egardless of the stem cell source. This leads us to
ropose for the future a consensus multicenter pro-
ocol for unrelated donor transplants based on the
se of a common conditioning including Fludara-
ine, a drug inducing a profound recipient immune
uppression without paying the price of relevant
xtra-medullary toxicity. BCKNOWLEDGMENTS
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